These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 10603734)

  • 61. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection.
    Reiberger T; Aberle JH; Kundi M; Kohrgruber N; Rieger A; Gangl A; Holzmann H; Peck-Radosavljevic M
    Antivir Ther; 2008; 13(8):969-76. PubMed ID: 19195322
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
    Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
    Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Immunology of HCV infection: the causes of impaired cellular immune response and the effect of antiviral treatment].
    Pár G; Berki T; Pálinkás L; Balogh P; Szereday L; Halász M; Szekeres-Barthó J; Miseta A; Hegedus G; Mózsik G; Hunyady B; Pár A
    Orv Hetil; 2006 Apr; 147(13):591-600. PubMed ID: 16623441
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Specifically targeted antiviral therapy for hepatitis C virus.
    Parfieniuk A; Jaroszewicz J; Flisiak R
    World J Gastroenterol; 2007 Nov; 13(43):5673-81. PubMed ID: 17963291
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens.
    Sherman KE; Rouster SD; Stanford S; Blackard JT; Shire N; Koziel M; Peters M; Chung RT;
    J Infect Dis; 2010 Mar; 201(5):712-9. PubMed ID: 20105080
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Antiviral therapy of hepatitis C].
    Erhardt A; Petry W; Ebel M; Jablonowski H; Heintges T; Häussinger D
    Z Gastroenterol; 2000 Mar; 38(3):259-69. PubMed ID: 10768250
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
    Scott LJ; Perry CM
    Drugs; 2002; 62(3):507-56. PubMed ID: 11827565
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.
    Morishima C; Polyak SJ; Ray R; Doherty MC; Di Bisceglie AM; Malet PF; Bonkovsky HL; Sullivan DG; Gretch DR; Rothman AL; Koziel MJ; Lindsay KL;
    J Infect Dis; 2006 Apr; 193(7):931-40. PubMed ID: 16518754
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
    Sagnelli E; Pisaturo M; Martini S; Sagnelli C; Filippini P; Coppola N
    Expert Opin Pharmacother; 2014 Jul; 15(10):1337-49. PubMed ID: 24773464
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.
    Neumann A; Polis M; Rozenberg L; Jackson J; Reitano K; McLaughlin M; Koratich C; Dewar R; Masur H; Haagmans B; Kottilil S
    AIDS; 2007 Sep; 21(14):1855-65. PubMed ID: 17721093
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
    Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
    Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
    Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin.
    Andriulli A; Cursaro C; Cozzolongo R; Iacobellis A; Valvano MR; Mangia A; Minerva N; Bacca D; Stanzione M; Scuteri A; Montalto G; Andreone P
    J Viral Hepat; 2009 Jan; 16(1):28-35. PubMed ID: 18761603
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.
    Pawlotsky JM; Pellerin M; Bouvier M; Roudot-Thoraval F; Germanidis G; Bastie A; Darthuy F; Rémiré J; Soussy CJ; Dhumeaux D
    J Med Virol; 1998 Apr; 54(4):256-64. PubMed ID: 9557291
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Therapy Implications of Hepatitis C Virus Genetic Diversity.
    Martinez MA; Franco S
    Viruses; 2020 Dec; 13(1):. PubMed ID: 33383891
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prediction of hepatitis C virus interferon/ribavirin therapy outcome based on viral nucleotide attributes using machine learning algorithms.
    KayvanJoo AH; Ebrahimi M; Haqshenas G
    BMC Res Notes; 2014 Aug; 7():565. PubMed ID: 25150834
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.
    Seeff LB; Hoofnagle JH
    Clin Liver Dis; 2003 Feb; 7(1):261-87. PubMed ID: 12691470
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Hepatitis C and G co-infection: response to interferon therapy and quantitative changes in serum HGV-RNA.
    McHutchison JG; Nainan OV; Alter MJ; Sedghi-Vaziri A; Detmer J; Collins M; Kolberg J
    Hepatology; 1997 Nov; 26(5):1322-7. PubMed ID: 9362379
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches.
    Ballesteros AL; Franco S; Fuster D; Planas R; Martínez MA; Acosta L; Sirera G; Salas A; Tor J; Rey-Joly C; Clotet B; Tural C
    AIDS; 2004 Jan; 18(1):59-66. PubMed ID: 15090830
    [TBL] [Abstract][Full Text] [Related]  

  • 80. IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients.
    El Awady MK; Bader El Din NG; Tabll A; El Hosary Y; Abdel Aziz AO; El Khayat H; Salama M; Abdelhafez TH
    World J Gastroenterol; 2013 Jan; 19(2):290-8. PubMed ID: 23345953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.